![5-Bromo-1H-pyrazolo[3,4-b]pyridine](/upload/1124/V66895.png)
| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a synthetic building block, 5-Bromo-1H-pyrazolo[3,4-b]pyridine does not target a specific protein or enzyme. Its utility is as a chemical intermediate for the preparation of bioactive molecules. The compound has been referenced in patent applications related to protein kinase inhibitors for promoting liver regeneration and heterocyclic compounds for the treatment of epilepsy, indicating that derivatives may have biological activities.
|
|---|---|
| ln Vitro |
The in vitro activity of 5-Bromo-1H-pyrazolo[3,4-b]pyridine is its function as a chemical building block for organic synthesis. The compound is a biochemical reagent that can be used as a biomaterial for life science related research. Its bromine substituent provides a handle for further functionalization through cross-coupling reactions, enabling the synthesis of various pharmaceutical compounds and bioactive molecules.
|
| ln Vivo |
No significant in vivo activity has been reported for 5-Bromo-1H-pyrazolo[3,4-b]pyridine as a therapeutic agent. The compound is primarily utilized as a chemical intermediate and research reagent rather than a pharmacologically active compound.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed for 5-Bromo-1H-pyrazolo[3,4-b]pyridine, as it functions as a chemical building block rather than a drug candidate. The compound is used in organic synthesis reactions where it serves as a precursor for the preparation of more complex molecules.
|
| Cell Assay |
For in vitro cellular experiments, 5-Bromo-1H-pyrazolo[3,4-b]pyridine is not typically used in cell-based assays. The compound is primarily used as a chemical intermediate in organic synthesis.
|
| Animal Protocol |
In vivo animal experiments with 5-Bromo-1H-pyrazolo[3,4-b]pyridine are not commonly performed, as the compound is primarily used as a chemical building block rather than a therapeutic candidate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5-Bromo-1H-pyrazolo[3,4-b]pyridine have not been characterized, as it is a research-use chemical intermediate rather than a drug candidate. The compound has a molecular weight of 198.02 g/mol, a boiling point of 329°C at 760 mmHg, and a density of 1.894 g/cm³. It should be stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
The compound has a GHS hazard statement H302 (Harmful if swallowed). Toxicological data indicates it may be harmful if ingested. It is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed, including P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501.
|
| Additional Infomation |
5-Bromo-1H-pyrazolo[3,4-b]pyridine is a useful building block in organic synthesis for the preparation of 7-azaindazole chalcone derivatives as analgesics and anti-inflammatories. It has been referenced in patent applications for protein kinase inhibitors and heterocyclic compounds for epilepsy treatment. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C6H4BRN3
|
|---|---|
| Molecular Weight |
198.02
|
| Exact Mass |
196.958
|
| CAS # |
875781-17-2
|
| PubChem CID |
40427454
|
| Appearance |
White to yellow solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
329.0±22.0 °C at 760 mmHg
|
| Melting Point |
198.0 to 202.0 °C
|
| Flash Point |
152.8±22.3 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.746
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
130
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C=C2C(NN=C2)=NC=1
|
| InChi Key |
BASYLPMLKGQZOG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H4BrN3/c7-5-1-4-2-9-10-6(4)8-3-5/h1-3H,(H,8,9,10)
|
| Chemical Name |
5-bromo-1H-pyrazolo[3,4-b]pyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0500 mL | 25.2500 mL | 50.4999 mL | |
| 5 mM | 1.0100 mL | 5.0500 mL | 10.1000 mL | |
| 10 mM | 0.5050 mL | 2.5250 mL | 5.0500 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
